Introduction The optimal timing of primary and metastatic tumor management in patients with synchronous hepatic colorectal metastases remains controversial. We aimed to compare perioperative outcomes of simultaneous colorectal/liver resection (SCLR) with isolated resections utilizing a national clinical database. Methods NSQIP data from 2005 to 2009 were examined to construct risk-adjusted generalized linear models and to calculate group-specific predicted estimates. These were used to compare 30-day perioperative outcomes among patients undergoing SCLR with colorectal (CR) and liver resections (LR) only in patients with metastatic colorectal cancer. Results A total of 3,983 patients were identified, who underwent SCLR (192), LR (1,857), or CR (1,934). Rectal resection was performed in 45 (23.4 %) SCLR patients and 269 (13.9 %) CR patients (p<0.001). Major hepatectomy was performed in 69 (35.9 %) SCLR patients and 774 (41.7 %) LR patients (p00.12). Median adjusted operation time (SCLR: 273 min, 95 % CI: 253-295; CR: 172, CI: 168-177; LR: 222, CI: 217-228; p<0.001) and median adjusted length of hospital stay (SCLR: 9.5 days, CI: 8.8-10.4; CR: 8.1, CI: 7.9-8.3; LR: 6.4, CI: 6.3-6.6; p<0.001) were longer for SCLR compared to CR and LR. Adjusted predicted risks for at least one postoperative complication were higher in SCLR (36.3 %) than in CR (26.6 %) and LR (19.8 %) (p<0.003), mostly due to infectious/ cardiopulmonary issues. Discussion In SCLR patients, the risk of 30-day adverse outcomes is higher, and median operation time as well as length of hospital stay is longer compared to CR and LR patients. However, the expected combined morbidities of staged procedures though likely favor SCLR in carefully selected patients undergoing even complex hepatic and colorectal resections and should be considered.
Introduction
Colorectal cancer is one of the most prevalent malignancies throughout the world and especially in the USA. 1 Among those patients, about 20 % present at diagnosis already with synchronous liver metastases, while 30-40 % develop hepatic metastases in the follow-up. 2, 3 Patients with unresected metastasis of colorectal cancer have a poor 5-year survival of less than 5 %, 4 while patients with completely resected colorectal cancer can achieve a 5-year survival rate of up to 58 % even after partial hepatectomy. [5] [6] [7] [8] [9] Historically, patients were managed with resection of the primary and subsequent systemic therapy prior to consideration of hepatectomy in order to best select patients for this complex and potentially morbid procedure. However, recent evidence suggests that simultaneous colorectal/liver resection (SCLR) of the primary tumor and the liver metastases might be an attractive option, 10 but the safety of this strategy has not been explored outside of modest single or multiinstitutional experiences.
Significant progress in the field of liver surgery including resection techniques, perioperative care, preoperative imaging, and better systemic therapies has helped to solidify and expand the role of partial hepatectomy in the management of patients with colorectal metastases. Although high-volume centers routinely report perioperative mortality rates of 1-3 %, [10] [11] [12] [13] broader datasets continue to report an overall mortality for major hepatectomies in the USA of approximately 7 %. 14 Overall, severe morbidity rates of approximately 20-30 % are routinely reported and highlight the need to identify ways in which to improve perioperative outcomes. The rising attractiveness of SCLR is supported by the fact that overall survival comparing simultaneous and staged resections of liver metastases shows comparable outcomes in single small multicenter studies. [15] [16] [17] [18] [19] [20] The primary goal of this investigation was to compare 30-day perioperative outcomes in patients with metastatic colorectal cancer undergoing SCLR with isolated resections. Using a more inclusive national clinical database, we sought to achieve a more generalizable picture of the short-term outcomes for SCLR.
Methods
The Institutional Review Board (IRB) at Duke University approved the study protocol. This secondary data analysis was conducted using the publicly available American College of surgeons National Surgical Quality Improvement Program (ACS-NSQIP) from 2005 to 2009. The ACS-NSQIP data collect information of over 200 hospitals on a volunteer basis and capture 240 variables including data on preoperative risk factors, intraoperative data, and 30-day postoperative morbidity and mortality. In the year 2009, 336,190 patient records were collected. Patient data are extracted through trained personnel, and Inter-Rater Reliability Audits are performed on a regular basis.
We included patients 18 years and older diagnosed with metastatic colorectal cancer who underwent a tumordirected resection and patients undergoing liver resection for metastatic disease. We then grouped the patients into three distinct groups: (1) isolated colorectal resection for metastatic colorectal cancer only (CR), (2) isolated liver resection for secondary cancer to the liver (LR), and (3) simultaneous colorectal resection and a liver resection due to colorectal cancer (SCLR). Patient identification was performed through a two-step approach. First, we identified colorectal cancer patients and patients with secondary cancer to the liver through the following ICD-9-CM diagnosis codes ( Patient baseline characteristics from ACS-NSQIP were extracted as follows: gender, ethnicity (white, black, Hispanic, other), age, body mass index (BMI, calculated from height and weight), alcohol and smoking status, neoadjuvant radio-(last 90 days) or chemotherapy (last 30 days), diabetes (no, oral medication, insulin dependency), COPD, relevant heart disease (congestive heart failure, myocardial infarction, percutaneous coronary intervention, history of angina pectoris), arterial hypertension requiring medication, peripheral arterial disease, dialysis, central nervous system disease (impaired sensorium, coma >24 h, hemiplegia, history of transient ischemic attacks, cerebrovascular insult with and without neurological deficit, tumor involving the central nervous system, paraplegia, quadriplegia), dyspnea, weight loss >10 % in the last 6 months, and ASA score (grouped: 1/2, 3, or higher). We also extracted and grouped the following laboratory values: albumin (<3.0, ≥3.0 g/dl), creatinine (≤1.5, >1.5 mg/dl), and sodium (<136, ≥136 mmol/l). Anemia was defined as a hematocrit <36.1 % for males and <40.7 % for females.
The following perioperative outcomes were extracted: superficial surgical site infection (SSI), deep incisional SSI/wound disruption, organ space SSI, any cardiopulmonary complication (pneumonia, unplanned intubation, longer than 48 h on mechanical ventilation, cardiac arrest requiring reanimation, myocardial infarction), any renal complication (progressive renal failure, acute renal failure, urinary tract infection), any CNS complication (stroke, coma >24 h), any thrombo-embolic event (deep vein thrombosis/thrombophlebitis, pulmonary embolism), and any septic complication (sepsis, septic shock). The number of individual complications was calculated from the aforementioned adverse outcomes and continuously grouped from 0 to 6 or higher. Data on mortality, return to the operating room, and if intraoperative red blood cell products were given were also collected. We also extracted the following periods: duration from anesthesia start to surgery start, duration from surgery stop to anesthesia stop, duration of patients in the operating room, total duration of anesthesia and operation, and length of hospital stay.
Statistical Analysis
Baseline characteristics among SCLR, CR, and LR patients were compared using ANOVA for continuous and chisquare test for categorical variables.
We compared frequencies of perioperative outcomes among SCLR, CR, and LR, unadjusted analyses using chisquare test for categorical and linear regression for continuous outcomes. Given the right skewness of the periodic outcomes, we used log transformation. The estimates were then re-transformed using the exponential formula, and median values as well as the 95 % confidence intervals are provided. 21 Adjusted comparisons of dichotomous and continuous perioperative outcomes among SCLR, CR, and LR patients were performed using multivariable logistic and linear regression models, respectively. Adjustment was performed using covariates defined a priori including defined covariates: gender, ethnicity, age, BMI, smoking status, number of comorbidities, dyspnea, ASA score, preoperative weight loss, preoperative radio-/chemotherapy, hypoalbuminemia (<3.0 g/dl), hypercreatinemia (>1.5 mg/dl), anemia (hematocrit <36.1 % for males and <40.7 % for females), and hyponatremia (<136 mmol/l). Multivariable-adjusted predicted risks of experiencing one of the dichotomous perioperative outcomes for patients undergoing SCLR, CR, and LR were calculated. The comparison among the number of individual postoperative complications across SCLR, CR, and LR was performed using a count model with a negative binomial regression distribution family. Negative binomial regression performed better than the Poisson regression and the zero-inflated negative binomial regression according to the Bayesian information criterion (BIC).
Subgroup analyses for main outcomes between SCLR and LR for major and minor hepatectomies were performed using the same analytical strategy as described previously. In addition, we assessed predictors of postoperative adverse outcomes among SCLR patients using unadjusted and multivariable-adjusted logistic regression analyses having at least postoperative complication as the outcome variable.
Sensitivity Analyses
The laboratory variables (albumin, creatinine, hematocrit, and sodium) demonstrated overall a missing rate of 19.2 %. We therefore performed sensitivity analyses excluding the laboratory variables as covariates from all adjusted analyses comparing the short-term postoperative outcomes.
A significance level (alpha) of 0.05 was used for all analyses. P-values (p) for all tests were two-sided. Results of regression analysis are provided as odds ratio (OR) and 95 % confidence intervals (CI). All statistical calculations were performed using Stata/SE version 11.2 (Stata Corporation, College Station, TX).
Results
Data from a total of 3,983 patients with metastatic colorectal cancer disease were evaluated, 192 (4.8 %) patients were in the SCLR, 1,934 (48.6 %) in the CR, and 1,857 (46.6 %) in the LR group. Most patients were male (n02,133, 53.6 %) and white (n03,089, 77.6 %), the overall mean age was 61.5 years (SD: 12.7), and the mean BMI was 27.6 kg/m 2 (SD: 6.3) ( Table 1 ). More SCLR patients underwent a rectal resection (n045; 23.4 %) than CR patients (n0269; 13.9 %) (p<0.001).
No difference in relation to the rate of major hepatectomies was detected among SCLR and LR patients (p00.12).
Unadjusted Analyses
In unadjusted analyses, the three groups differed for the following perioperative outcomes: superficial SSI, deep incisional SSI, organ space SSI, any SSI, renal complications, septic complications, number of postoperative complications, use of red blood cells, rate of return to the operating room, and mortality (Table 2) . Compared to SCLR patients, the time duration from the beginning of anesthesia to the start of surgery as well as the duration from the end of surgery to the end of anesthesia was shorter in the CR group, while no such difference was detected compared to the LR group (Table 3) . The median operation time was longer in SCLR (304 min) than in CR (165 min) and LR (226 min), p<0.001 for both analyses. Median length of stay was longer in SCLR (9.34 days) than in CR (8.29 days) and LR (6.13 days), p<0.006 for both analyses.
Adjusted Analyses and Predicted Values
In adjusted analyses, the odds of having any surgical site infection were significantly lower for CR (OR: 0.62, CI: 0.41-0.94, p00.025) and for LR (OR: 0.33, CI: 0.22-0.51, p<0.001) compared to SCLR (Table 4 ). The sum of the adjusted predicted risks for CR and LR was similar to the predicted risk for SCLR. In addition, lower odds for cardiopulmonary complications for CR (OR: 0.38, CI: 0.21-0.68, p00.001) and LR (OR: 0.47, CI: 0.26-0.83, p00.009) were found compared to SCLR, as well as lower septic complications (CR; OR: 0.43, CI: 0.26-0.71, p00.001; LR; OR: (Table 5) .
Predictors of Adverse Outcomes Among SCLR Patients
In adjusted analyses, the only significant predictor of at least one postoperative complication was any comorbidity (OR: 3.29, CI: 1.65-6.53, p00.001). All other potential predictors did not show a significant association with adverse postoperative complications, including minor/major hepatectomy (OR: 1.11, CI: 0.57-2.15, p00.76) ( Table 6 ).
Sensitivity Analysis
The vast majority of the estimates did not significantly differ after excluding the laboratory values as covariates from the multivariable analyses. There were three results where the significance level changed. First, the adjusted odds ratio of superficial SSI comparing SCLR to LR was 0.53 (CI: 0.29-0.97, p00.04); second, the adjusted odds ratio for return to operating room comparing SCLR to CR was 1.95 (CI: 0.94-4.07, p00.08); and third, in the subgroup analysis of major hepatectomies, the odds ratio of any septic complication was 0.46 (CI: 0.21-0.98, p00.046).
Discussion
To our knowledge, this is the first large-scale study assessing perioperative outcomes among patients undergoing SCLR versus isolated CR and LR. Using the NSQIP dataset, this investigation provides strong evidence that patients undergoing SCLR have more perioperative adverse outcomes, longer operation times, and longer hospital stays than patients undergoing isolated CR and LR. The higher risk of perioperative adverse outcomes comparing SCLR and LR patients holds true for both major and minor hepatectomies, while the sum of adverse outcomes of CR and LR might be higher than those for SCLR. However, the comparison of the combination of CR and LR versus SCLR favors SCLR over the staged approach-a confirmation that SCLR is not only an attractive option but might rather be the treatment strategy of choice in selected patients. In the contemporary management of patients with synchronous hepatic colorectal metastases, a growing body of literature supports a multimodality approach whereby patients undergo resection of primary and metastatic sites, systemic therapy, and, in selected patients, radiotherapy. 9, 10, [22] [23] [24] [25] [26] [27] The appropriate timing of the various interventions is a topic of significant debate. The classical therapeutical pathway to this disease foresees patients first undergoing the primary tumor resection (in rectal patients following chemoradiation) followed by systemic therapy of an arbitrary duration, typically 6 months or longer. In this classical pathway, resection of hepatic metastases is then performed only if the indication for resection remains. A growing body of literature suggests that alternative approaches may be reasonable. 10, 15, 18, 27 A number of authors have suggested that the hepatic metastases are to be prioritized over minimally symptomatic primary tumors and that early interventions should be focused on achieving complete extirpation of the hepatic metastases. 28, 29 For many patients, especially those with marginally resectable hepatic metastases and those with significant hepatic tumor burdens, the initial intervention should be contemporary multidrug systemic therapy. 30 The observation that patients with non-resectable metastatic disease do not need to have their primary tumors resected as a matter of routine supports this 
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Adjustment performed for gender, ethnicity, age, BMI, smoking status, comorbidity, dyspnoe, ASA score, preoperative weight loss, preoperative radio-/chemotherapy, hypoalbuminemia, hypercreatinemia, anemia, hyponatremia. N/A: not applicable for adjusted analysis due to low frequency in the SCLR group prioritization. For many patients with synchronous hepatic metastases, the initial prioritization of the hepatic metastases will lead to situations where simultaneous hepatic resections may be considered. As a general summary, the existing literature from modest single or limited multiinstitutional studies suggests that the combined morbidity of staged colorectal and hepatic resections is greater than simultaneous resections, especially in patients requiring lower complexity Adjustment performed for gender, ethnicity, age, BMI, smoking status, comorbidity, dyspnea, ASA score, preoperative weight loss, preoperative radio-/chemotherapy hepatic procedures. 10, 27 From an oncologic perspective, there often exists a perception that patients with synchronous metastases are at greater risk for early progression following partial hepatectomy and, for that reason, should only undergo hepatic resection following extended periods of selection with systemic therapy. Recent studies have reported that the overall 5-year survival rates for patients undergoing SCLR at highvolume centers are as high as 53 %, which is comparable to a completed staged approach of isolated CR and LR. [15] [16] [17] [18] [19] [31] [32] [33] [34] Nonetheless, whether the experiences of high-volume centers as described in these limited reports can be generalized across a larger population of patients is not clear especially in light of the fact that the incidence of postoperative complications after liver resections appears to be directly correlated with overall survival [ 5 ] . Our analysis shows that adverse short-term complications among hospitals reporting to NSQIP are substantially higher for patients undergoing SCLR than for patients undergoing isolated LR. This is in contrast to many other single-center investigations which report that SCLR has similar if not lower postoperative complication rates compared to LR, 15, 16, 18, 32, 35, 36 while a minority also showed higher postoperative adverse outcomes for patients undergoing SCLR than LR alone. 10, 17 However, the comparison of SCLR should not be only to LR, but the entire staged treatment regimen. Comparing the predicted estimates of complications from CR and LR together versus the predicted complications of SCLR demonstrates that SCLR fares better in several outcomes measures. This finding is supported by previous studies. 10, 35, 36 Because NSQIP data do not contain patient identifiers, it is not possible to directly combine patients undergoing CR and LR to create a patient subset of staged resection. However, pooling of the multivariable-adjusted predicted estimates for CR and LR allows an informal comparison of CR and LR to SCLR. This approach might even have substantial benefits over the pure comparison of SCLR to the staged procedure since it likely includes also patients who were planned to undergo a staged treatment but did not successfully complete both surgeries for one of the following reasons: patients whose overall condition after CR did not allow performing LR, patients with tumor progression not enabling a complete tumor resection anymore, or patients died before the planned liver resection. Only including patients completing CR and LR might lead to a substantial selection bias favoring the staged procedure since only patients with an advantageous disease progression and beneficial recovery after CR will undergo LR at a later time-point. 37 However, if including those patients to the comparator group for SCLR would even lead to a survival benefit for SCLR remains highly speculative.
In early experiences of SCLR, patients were more apt to be limited to right-sided colectomies and minor hepatectomies. 38 In more contemporary experiences, left-sided colectomies and rectal resections and major hepatectomies are described in greater frequency with excellent outcomes. 16 However, Reddy et al. suggested in a multiinstitutional analysis that patients undergoing SCLR only benefit from this simultaneous approach if a minor simultaneous hepatectomy is performed. In their report, patients requiring more complex hepatectomies (≥3 segments) experienced more postoperative adverse outcomes than patients undergoing the staged approach. 10 Our results suggest that SCLR has significantly more adverse outcomes than isolated LR for both minor and major hepatectomies. However, comparing the results of the predicted combined risks for staged CR and LR versus SCLR suggests an increased overall complication rate that is higher for the staged approach even when more complex procedures are involved. The fact that only one patient (1.5 %) died undergoing SCLR with major hepatectomy highlights that this procedure can be performed safely. In other analyses, however, major hepatectomy in SCLR was a significant predictor of mortality, 10, 32, 39 but not in others. 16, 17, 36, 40 In sum, our results suggest that SCLR can be recommended in carefully selected patients undergoing both major and minor hepatectomies. What is not clear though is how to best select candidates for SCLR. The authors would readily admit that SCLR is not appropriate for all patients requiring complex hepatic and/or colorectal resections. Nonetheless, in patients where the complex procedures appear to be relatively straightforward, SCLR should be considered.
There are a number of limitations that should be acknowledged. First, using the NSQIP dataset, it is only possible to identify patients with secondary cancers to the liver, but it is not possible to further limit those patients with colorectal metastasis. However, the majority of liver resections performed for secondary cancers are performed due to colorectal liver metastasis. Second, because patient identifiers are missing in NSQIP, it is also not possible to track patients over time. It is therefore not possible to distinguish between synchronous and metachronous liver metastasis. However, 30-day postoperative outcomes might not differ if a patient undergoes a liver resection for either underlying disease. Given our inability to track patients over time, the sum of complications of CR and LR can only be considered an approximation of what could be expected as the total number of complications if a staged approach were to be planned. Third, complication severity is not captured in the NSQIP dataset. It is therefore possible that any of one group might have had complications that were more severe than their counterparts. Finally, due to the retrospective nature of the analysis, we were limited to the covariates available in the dataset and additional confounding cannot be ruled out.
Conclusion
Among hospitals reporting outcomes to NSQIP, the risk of 30-day adverse outcomes for SCLR is significantly higher than that for CR and LR. The expected combined morbidities of staged procedures though likely favors SCLR in carefully selected patients undergoing even complex hepatic and colorectal resections and should be considered. Further studies addressing the long-term outcomes of this approach are necessary to ensure its proper role in the management of these complex patients.
